Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.43 |
| ▸ | CYBB | P04839 | 1/20 | 0.43 |
| ▸ | NOX3 | Q9HBY0 | 1/20 | 0.43 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 5/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | JUN | P05412 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30811586 | 0.91 | KIF11 (0.49) | ACE2NOX1CYBBNOX3NOX4 | |
| SCHEMBL29636446 | 0.91 | ALOX5 (0.59) | ACE2NOX1CYBBNOX3NOX4 | |
| SCHEMBL18614108 | 0.91 | ALOX5 (0.59) | ACE2NOX1CYBBNOX3NOX4 | |
| SCHEMBL27344289 | 0.91 | KIF11 (0.49) | ACE2NOX1CYBBNOX3NOX4 | |
| SCHEMBL31512592 | 0.85 | TAAR1 (0.42) | ACE2NOX1CYBBNOX3NOX4 | |
| SCHEMBL30811571 | 0.85 | ACE2 (0.49) | ACE2NOX1CYBBNOX3NOX4 | |
| SCHEMBL27344608 | 0.85 | ACE2 (0.46) | ACE2NOX1CYBBNOX3NOX4 | |
| SCHEMBL31512645 | 0.85 | ACE2 (0.40) | ACE2NOX1CYBBNOX3NOX4 | |
| SCHEMBL27344609 | 0.85 | ACE2 (0.46) | ACE2NOX1CYBBNOX3NOX4 | |
| SCHEMBL27344606 | 0.85 | ACE2 (0.46) | ACE2NOX1CYBBNOX3NOX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11261403-B2 | Stabilized compositions comprising leuco compounds | MILLIKEN & COMPANY (US) | 2022-03-01 | — | — | US | claimed |
| US-11136535-B2 | Leuco colorants as bluing agents in laundry care compositions | THE PROCTER & GAMBLE COMPANY (US) | 2021-10-05 | — | — | US | claimed |
| EP-3830232-A1 | LEUCO COLORANTS AS BLUING AGENTS IN LAUNDRY CARE COMPOSITIONS | The Procter & Gamble Company (US) | 2021-06-09 | — | — | EP | claimed |
| US-20200032173-A1 | LEUCO COLORANTS AS BLUING AGENTS IN LAUNDRY CARE COMPOSITIONS | THE PROCTER & GAMBLE COMPANY | 2020-01-30 | — | — | US | claimed |
| WO-2020023812-A1 | LEUCO COLORANTS AS BLUING AGENTS IN LAUNDRY CARE COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2020-01-30 | — | — | WO | claimed |
| US-20200032167-A1 | STABILIZED COMPOSITIONS COMPRISING LEUCO COMPOUNDS | MILLIKEN & COMPANY | 2020-01-30 | — | — | US | claimed |
| US-20230392018-A1 | COMPOSITIONS COMPRISING LEUCO COMPOUNDS AND COLORANTS | MILLIKEN & COMPANY | 2023-12-07 | — | — | US | disclosed |
| EP-4237498-A1 | COMPOSITIONS COMPRISING LEUCO COMPOUNDS AND COLORANTS | Milliken & Company (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3347355-B1 | HETEROTRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3347355-B1 | HETEROTRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2022-07-13 | — | — | EP | disclosed |
| WO-2022093189-A1 | COMPOSITIONS COMPRISING LEUCO COMPOUNDS AND COLORANTS | MILLIKEN & COMPANY (US) | 2022-05-05 | — | — | WO | disclosed |
| US-11261403-B2 | Stabilized compositions comprising leuco compounds | MILLIKEN & COMPANY (US) | 2022-03-01 | — | — | US | disclosed |
| US-11136535-B2 | Leuco colorants as bluing agents in laundry care compositions | THE PROCTER & GAMBLE COMPANY (US) | 2021-10-05 | — | — | US | disclosed |
| US-20180251456-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-09-06 | — | — | US | disclosed |
| EP-3347355-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | Icahn School of Medicine at Mount Sinai (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-3331867-A1 | STEREOSPECIFIC PROCESS FOR 3-HETEROCYCLYLCYCLOALIPHATIC-1,2-DIOLS | Icahn School of Medicine at Mount Sinai (US) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017044569-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017044569-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017024229-A1 | STEREOSPECIFIC PROCESS FOR 3-HETEROCYCLYLCYCLOALIPHATIC-1,2-DIOLS | ICAHN SCHOOL OF MEDECINE AT MOUNT SINAI (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017024229-A1 | STEREOSPECIFIC PROCESS FOR 3-HETEROCYCLYLCYCLOALIPHATIC-1,2-DIOLS | ICAHN SCHOOL OF MEDECINE AT MOUNT SINAI (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251456-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | FOXO1, HDAC3, HDAC6 | ACE2 4358/4885NOX1 2743/4885CYBB 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.